Digest Data on Nektar-AstraZeneca’s Naloxegol – Barron’s

by admin on May 23, 2013

Digest Data on Nektar-AstraZeneca's Naloxegol
Barron’s
Nektar has a significant Phase II catalyst in the third quarter, namely data from NKTR-181 in chronic pain patients, which we believe will be highly positive. Synergy announced full results from its Phase IIb/III trial of plecanatide for chronic

and more »

View full post on chronic pain – Google News

Previous post:

Next post: